Kinase Inhibitor Discovery
with an untiring quest for future therapeutics

Submission of Investigational New Drug Application for AS-1763 (BN102) in China by BioNova

Carna Announces Initiation of MAD study of Phase 1 Clinical Study for AS-0871

Updated the pipeline following the advancement of the program out-licensed to Gilead and our STING antagonist program.

Revision of Results Forecast for the Fiscal Year Ending December 31, 2021

Carna Receives First Milestone Payment from Gilead

Carna Announces to Extend the Agreement with Sumitomo Dainippon Pharma on Joint Research, Development, and Commercialization of Kinase Inhibitors

Carna Announces Initiation of BA part of Phase 1 Clinical Study for AS-1763

FY2021 Q3 Presentation